Integration of AMR Surveillance into Pharmacovigilance Frameworks

The traditional pharmacovigilance paradigm is centered on detecting adverse drug reactions (ADRs)—harmful and unintended responses to a drug used at normal doses. AMR, however, represents a reduction in a drug’s intended clinical benefit. This fundamental shift—from monitoring safety to monitoring efficacy failure due to resistance—requires a significant evolution in PV practices.

Here’s a detailed breakdown of how this can be achieved:

1. Expanding the PV Data Universe: From Spontaneous Reports to Integrated Data Streams

Traditional PV relies heavily on spontaneous reporting. For AMR, this is necessary but insufficient. An advanced framework must integrate multiple data sources:

• Enhanced Spontaneous Reporting: Encourage and standardize the reporting of suspected treatment failure. A report should not just state “patient had a rash,” but “patient with confirmed UTI failed to respond to ciprofloxacin despite 5 days of therapy; culture revealed resistant E. coli.”
  • Key Data Points: Suspect drug, indication, microbiological data (pathogen, susceptibility testing), clinical outcome (failure, relapse).
• Linkage with Microbiology and Laboratory Data: This is the cornerstone. PV systems must create automated or semi-automated interfaces with hospital Laboratory Information Systems (LIS).
  • Automated Signal Generation: An algorithm can be designed to flag cases where a patient is prescribed an antibiotic and a subsequent culture shows the infecting pathogen is non-susceptible to that drug. This becomes a potential “efficacy ADR.”
• Leveraging Real-World Data (RWD):
  • Electronic Health Records (EHRs): Analyze longitudinal data to identify patterns. For example, a cluster of patients in a specific region with similar infections (e.g., pneumococcal pneumonia) failing first-line antibiotics.
  • Claims and Pharmacy Data: Identify trends where prescriptions for second-line or broader-spectrum antibiotics are rapidly increasing for a common indication, suggesting first-line treatment failure.
• Active Surveillance and Registries: Establish targeted, active surveillance programs for specific drug-bug combinations of concern (e.g., carbapenem-resistant Enterobacteriaceae – CRE, or vancomycin-resistant Staphylococcus aureus – VRSA).

2. Advanced Signal Detection and Analysis: Beyond Disproportionality

Standard PV signal detection uses disproportionality analysis (e.g., measuring the Reporting Odds Ratio) to find unexpected ADRs. For AMR, the methodology must be more nuanced:

• Temporal and Geospatial Analysis: Signals must be analyzed over time and space. A slight, consistent increase in reports of ceftriaxone-resistant gonorrhea across multiple regions is a more critical signal than a single, high-profile report.
• Case-Population Analysis: Instead of just comparing drug-event pairs, analyze the rate of resistance reports per treatment course for a specific indication. A rising trend indicates growing resistance.
• Integrating Genomic Data: The most advanced approach involves incorporating whole-genome sequencing (WGS) data of pathogens. By linking a specific resistance gene (e.g., blaKPC for carbapenemase) to reports of treatment failure with a specific carbapenem, PV can move from describing the phenomenon to understanding the molecular mechanism and tracking its spread.

3. The Role of PV in Monitoring Effectiveness and Resistance Patterns

The PV function transforms from a passive receiver of reports to an active sentinel for population-level drug effectiveness.

• From Individual Cases to Population-Level Trends: The PV unit’s role is to aggregate individual cases of suspected treatment failure to identify emerging resistance trends. This information is critical for:
  • Updating Treatment Guidelines: Providing robust, real-world evidence to committees that national or hospital formularies need to change first-line recommendations.
  • Informing Drug Development: Alerting R&D departments about which resistance mechanisms are most pressing, guiding the development of next-generation antibiotics.
• Risk Management Planning: For new antibiotics, the Risk Management Plan (RMP) should include specific provisions for monitoring the emergence of resistance. This could involve:
  • Educational Materials: For prescribers, emphasizing the importance of culture and susceptibility testing before use.
  • Controlled Access Programs: Restricting use to certain hospital settings to preserve efficacy.
  • Post-Authorization Safety (and Efficacy) Studies (PASS/PAES): Specifically designed studies to monitor resistance development in real-world populations.

4. Integrating AMR Surveillance into Routine Drug Safety Processes

This requires systematic changes to the PV System Master File (PSMF) and Standard Operating Procedures (SOPs).

• Case Processing:
  • Coding: Use standardized MedDRA terms like “Therapeutic response decreased” and “Pathogen resistance.” Develop internal guidelines to consistently code AMR-related cases.
  • Expectedness: A case of treatment failure with a resistant organism might be “expected” from a safety perspective, but it is a critical “efficacy signal” that must be captured and analyzed separately.
• Periodic Safety Update Reports (PSURs)/Periodic Benefit-Risk Evaluation Reports (PBRERs):
  • Dedicate a specific section to “Evaluation of Efficacy and Emerging Resistance.” This section should present data on:
    • Volume of treatment failure reports.
    • Trends in minimum inhibitory concentration (MIC) values from linked lab data.
    • Geographic distribution of resistance reports.
    • Analysis of the impact on the product’s benefit-risk profile.
• Quality Management System (QMS):
  • Update SOPs to define the workflow for receiving, processing, and analyzing data from microbiology labs and other RWD sources.
  • Train PV personnel on basic microbiology and the principles of AMR to improve the quality of their case assessment.

Conclusion: The “One Health” PV System

The most advanced application recognizes that AMR transcends human medicine. Resistant bacteria circulate between humans, animals, and the environment. A truly robust PV framework for AMR will eventually need to adopt a “One Health” approach, integrating data from veterinary pharmacovigilance and environmental monitoring of antibiotic residues and resistant genes. By expanding its scope, leveraging advanced analytics, and embedding itself into the clinical workflow, pharmacovigilance can transform from a guardian of drug safety into a sentinel for antimicrobial efficacy and a cornerstone of the global fight against AMR.